癌症治疗对多囊卵巢综合征女性不孕风险及卵巢储备下降的影响
基于人群的队列研究(FUCHSIA女性研究)纳入1,090例22-45岁女性癌症幸存者及374例无癌女性,比较伴或不伴多囊卵巢综合征(PCOS)者的不孕、生育目标及卵巢储备指标。伴PCOS的幸存者接受或未接受性腺毒性治疗后报告不孕的比值比分别为2.3和3.4,且更少达到 desired 子女数;调整年龄后,无癌PCOS女性卵巢储备标志物最高,接受性腺毒性治疗的无PCOS幸存者最低。
要点
- 伴PCOS的癌症幸存者接受性腺毒性治疗后报告不孕的OR为2.3(95%CI 1.2-4.5),未暴露者为3.4(95%CI 1.7-6.9)。
- 伴PCOS幸存者更可能子女数少于期望(暴露OR 2.1,95%CI 1.0-4.2;未暴露OR 3.0,95%CI 1.4-6.8)。
- 调整年龄后,无癌PCOS女性AMH 2.43 ng/mL、AFC 20.7最高,接受性腺毒性治疗的无PCOS幸存者AMH 0.19 ng/mL、AFC 7.4最低。
核心结论
- 尽管癌症治疗后伴PCOS的幸存者平均AMH和AFC较高,但与无PCOS的幸存者相比,她们更不可能实现其生殖目标。
研究设计与样本
- FUCHSIA女性研究——基于人群的队列研究,纳入1,090例22-45岁、20-35岁确诊且确诊至少2年的女性癌症幸存者,其中369例完成门诊访视;374例无癌育龄女性也完成门诊访视。
主要发现
- 78例癌症幸存者(7.2%)报告PCOS诊断,其中41例接受性腺毒性治疗。
- 伴PCOS且接受性腺毒性治疗的幸存者报告不孕的OR为2.3(95%CI 1.2-4.5),未暴露者为3.4(95%CI 1.7-6.9),均高于未暴露且无PCOS的幸存者。
- 伴PCOS幸存者更可能子女数少于期望(暴露OR 2.1,95%CI 1.0-4.2;未暴露OR 3.0,95%CI 1.4-6.8)。
- 调整年龄后,无癌PCOS女性卵巢储备标志物最高(AMH 2.43 ng/mL,95%CI 1.22-4.82 ng/mL;AFC 20.7,95%CI 15.3-27.8)。
- 接受性腺毒性治疗的无PCOS癌症幸存者卵巢储备标志物最低(AMH 0.19 ng/mL,95%CI 0.14-0.26 ng/mL;AFC 7.4,95%CI 6.4-8.5)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare markers of fertility and ovarian reserve between cancer survivors and cancer-free women with and without polycystic ovary syndrome (PCOS). DESIGN: Furthering Understanding of Cancer, Health, and Survivorship in Adult (FUCHSIA) Women's Study-a population-based cohort study. SETTING: Not applicable. PATIENT(S): Female cancer survivors (n = 1,090) aged 22-45 years, diagnosed between ages 20 and 35 years, and at least 2 years after diagnosis; 369 participated in a clinic visit. Three hundred seventy-four reproductive-aged women without cancer also completed a clinic visit. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Infertility, time to first pregnancy after cancer diagnosis, and measures of ovarian reserve (antimüllerian hormone [AMH] and antral follicle count [AFC]). RESULTS: Seventy-eight cancer survivors (7.2%) reported a PCOS diagnosis, with 41 receiving gonadotoxic treatment. Survivors with PCOS exposed to gonadotoxic treatment (odds ratio [OR] 2.3, 95% confidence interval [CI] 1.2-4.5) and unexposed (OR 3.4, 95% CI 1.7-6.9) were more likely to report infertility than unexposed survivors without PCOS and were more likely to have fewer children than desired (exposed: OR 2.1, 95% CI 1.0-4.2; unexposed: OR 3.0, 95% CI 1.4-6.8). After adjusting for age, comparison women with PCOS had the highest markers of ovarian reserve (AMH: 2.43 ng/mL, 95% CI 1.22-4.82 ng/mL; AFC: 20.7, 95% CI 15.3-27.8), and cancer survivors without PCOS treated with gonadotoxic agents had the lowest levels (AMH: 0.19 ng/mL, 95% CI 0.14-0.26 ng/mL; AFC: 7.4, 95% CI 6.4-8.5). CONCLUSION(S): Despite having higher AMH and AFC on average after cancer treatment, cancer survivors with PCOS were less likely to meet their reproductive goals compared with survivors without PCOS.
引用
- Shandley LM, Fothergill A, Spencer JB, et al. Impact of cancer treatment on risk of infertility and diminished ovarian reserve in women with polycystic ovary syndrome. Fertil Steril. 2018. PMID: 29428311. doi:10.1016/j.fertnstert.2017.11.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。